Reducing cardiovascular disease risk in type 2 diabetes: is the focus on glycaemia warranted?

Area of Science:

• Endocrinology
• Cardiology
• Metabolic Diseases

Background:

• Cardiovascular disease (CVD) is a primary cause of death and disability in patients with type 2 diabetes mellitus (T2DM).
• Effective management strategies for T2DM complications are crucial for improving patient outcomes.
• The interplay between glycaemic control, blood pressure, and lipid management in mitigating CVD risk is a key area of research.

Purpose of the Study:

• To review current evidence on the impact of glycaemic control on cardiovascular and microvascular outcomes in T2DM.
• To compare the cardiovascular benefits of glycaemic control with those of blood pressure and statin management.
• To provide evidence-based recommendations for clinical practice regarding risk factor management in T2DM.

Main Methods:

• Systematic review of recent clinical trials and meta-analyses.
• Comparative analysis of evidence from glycaemic control, blood pressure, and statin interventions.
• Consideration of pragmatic factors in clinical decision-making.

Main Results:

• Glycaemic control shows less pronounced cardiovascular benefits compared to blood pressure and lipid management in T2DM.
• Patient characteristics significantly influence the risk-benefit ratio of intensive glycaemic reduction.
• Blood pressure and lipid management are identified as critical for reducing cardiovascular risk in this population.

Conclusions:

• Clinicians should prioritize aggressive blood pressure and lipid management to reduce cardiovascular risk in patients with T2DM.
• Future guidelines should emphasize the importance of lipid-lowering and blood pressure control, with individualized glycaemic targets.
• A shift in clinical focus towards comprehensive cardiovascular risk management, beyond glycaemic control alone, is warranted for T2DM patients.